MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 28, 2008; DOI: 10.1124/mol.108.045054


0026-895X/08/7403-552-561$20.00
Mol Pharmacol 74:552-561, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.045054v1
74/3/552    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Proulx, C. D.
Right arrow Articles by Leduc, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Proulx, C. D.
Right arrow Articles by Leduc, R.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ASPARTIC ACID

Mutational Analysis of the Conserved Asp2.50 and ERY Motif Reveals Signaling Bias of the Urotensin II Receptor

Christophe D. Proulx, Brian J. Holleran, Antony A. Boucard, Emanuel Escher, Gaétan Guillemette, and Richard Leduc

Department of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada

Class A (rhodopsin-like) G protein-coupled receptors possess conserved residues and motifs that are important for their specific activity. In the present study, we examined the role of residue Asp972.50 as well as residues Glu1473.49, Arg1483.50, and Tyr1493.51 of the ERY motif on the functionality of the urotensin II receptor (UT). Mutations D972.50A, R1483.50A, and R1483.50H abolished the ability of UT to activate phospholipase C, whereas mutations E1473.49A and Y1493.51A reduced the ability to activate PLC by 50%. None of the mutants exhibited constitutive activity. However, R1483.50A and R1483.50H promoted ERK1/2 activation, which was abolished by 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478), an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase activity. Both these mutants were capable of directly activating EGFR, which confirmed that they activated the mitogen-activated protein kinase (MAPK) pathway by a G{alpha}q/11-independent transactivation of EGFR. The D972.50A, R1483.50A, and R1483.50H mutants did not readily internalize and did not promote translocation or colocalize with β-arrestin2-GFP. Finally, the agonist-induced internalization of the E1473.49A mutant receptor was significantly increased compared with wild-type receptor. This study highlights the major contribution of the conserved Asp2.50 residue to the functionality of the UT receptor. The Arg residue in the ERY motif of UT is an important structural element in signaling crossroads that determine whether G{alpha}q/11-dependent and -independent events can occur.


Received for publication January 8, 2008.

Accepted for publication May 22, 2008.

Address correspondence to: Richard Leduc, Ph.D. Department of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, J1H 5N4, ON, Canada. E-mail: richard.leduc{at}usherbrooke.ca




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
I. Domazet, B. J. Holleran, S. S. Martin, P. Lavigne, R. Leduc, E. Escher, and G. Guillemette
The Second Transmembrane Domain of the Human Type 1 Angiotensin II Receptor Participates in the Formation of the Ligand Binding Pocket and Undergoes Integral Pivoting Movement during the Process of Receptor Activation
J. Biol. Chem., May 1, 2009; 284(18): 11922 - 11929.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics